載入...
Retrospective Toxicological Profiling of Radium-223 Dichloride for the Treatment of Bone Metastases in Prostate Cancer Using Adverse Event Data
Background and Objective: Radium-223 dichloride (Xofigo(®)) is a calcium mimetic agent approved for the treatment of castration-resistant prostate cancer patients with symptomatic bone metastases and no known visceral metastatic disease. This targeted, α-particle-emitting therapy has demonstrated si...
Na minha lista:
| 發表在: | Medicina (Kaunas) |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
MDPI
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6572036/ https://ncbi.nlm.nih.gov/pubmed/31100964 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/medicina55050149 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|